Rhythm Pharmaceuticals, Inc.
RYTM
Pozycja w akcjach
#2956
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Cena akcji
$90.58
Kapitalizacja rynkowa
$6.24B
Zmiana (1 dzień)
2.66%
Zmiana (1 rok)
-19.40%
Kraj
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Kategoria
Healthcare
Przychody dla Rhythm Pharmaceuticals, Inc. (RYTM)
Przychody w Jun 2026 TTM: $239.92M
Według najnowszych raportów finansowych Rhythm Pharmaceuticals, Inc., obecny przychód firmy (TTM) wynosi $239.92M. W roku 2023 firma osiągnęła przychód w wysokości $77.43M wzrost w porównaniu do przychodu z roku 2022, który wynosił $23.64M. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Rhythm Pharmaceuticals, Inc. od 2012 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $239.92M | 84.37% |
| 2024 | $130.13M | 68.06% |
| 2023 | $77.43M | 227.56% |
| 2022 | $23.64M | 649.46% |
| 2021 | $3.15M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $12.62B | 5,161.92% |
US
|
|
| $2.23B | 828.65% |
US
|
|
| $15.74B | 6,462.38% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,409.73% |
NL
|
